Breathe BioMedical Inc. is a medical technology company. It is focused on developing a breath test to be used as an adjunctive test to mammography screening to detect early-stage breast cancer in women with dense breast tissue. Breath analytics involves the collection, processing, and analysis of breath samples to identify biomarker patterns associated with specific diseases. It is developing a proprietary end-to-end breath analytics platform, the intended use of which is to enable breath testing for the detection of disease. Its platform technology combines three advanced technologies to sample, digitize and analyze breath with the potential to detect multiple diseases. Its spectrometer technology uses Cavity Ring-Down Spectroscopy (CRDS) to measure the volatile organic compounds (VOCs) in breath samples which are collected using its breath sampler device (SohnoXB). Spectrometer is designed to be very fast, permitting sample analysis down to parts-per-trillion levels.
公司代码BRTH
公司Breathe BioMedical Ord Shs (Proposed)
CEODawes (William)
网址https://breathebiomedical.com/
常见问题
Breathe BioMedical Ord Shs (Proposed)(BRTH)的当前股价是多少?
Breathe BioMedical Ord Shs (Proposed)(BRTH)的当前股价是 --。
Breathe BioMedical Ord Shs (Proposed)的股票代码是什么?
Breathe BioMedical Ord Shs (Proposed)的股票代码是BRTH。
Breathe BioMedical Ord Shs (Proposed)股票的52周最高点是多少?
Breathe BioMedical Ord Shs (Proposed)股票的52周最高点是--。
Breathe BioMedical Ord Shs (Proposed)股票的52周最低点是多少?
Breathe BioMedical Ord Shs (Proposed)股票的52周最低点是--。
Breathe BioMedical Ord Shs (Proposed)的市值是多少?
Breathe BioMedical Ord Shs (Proposed)的市值是--。
Breathe BioMedical Ord Shs (Proposed)的净利润是多少?
Breathe BioMedical Ord Shs (Proposed)的净利润为--。
现在Breathe BioMedical Ord Shs (Proposed)(BRTH)的股票是买入、持有还是卖出?
根据分析师评级,Breathe BioMedical Ord Shs (Proposed)(BRTH)的总体评级为--,目标价格为--。
Breathe BioMedical Ord Shs (Proposed)(BRTH)股票的每股收益(EPS TTM)是多少
Breathe BioMedical Ord Shs (Proposed)(BRTH)股票的每股收益(EPS TTM)是--。